Dynamics of circulating tumor cell subsets defined by PSMA and EpCAM predict survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617

In the battle against advanced prostate cancer, doctors often face a shifting enemy. The disease, when it has spread beyond the prostate and resists standard hormone therapies, is known as metastatic castration-resistant prostate cancer. For years, treatment options were limited, but a newer approach has emerged that acts like a guided missile. This treatment uses a radioactive substance attached to a molecule that seeks out a specific protein called PSMA, which sits on the surface of many prostate cancer cells. When the radioactive molecule finds its target, it delivers a dose of radiation directly to the tumor, sparing much of the surrounding healthy tissue. While this method has shown great promise, doctors still need to understand how the cancer cells themselves change and react during the treatment. Do the cells disappear? Do they transform into something harder to catch? Answering these questions could help predict which patients will live longer and which might need a different plan sooner.

To find these answers, researchers recently tracked the movement of cancer cells as they traveled through the bloodstream. Instead of looking at the tumors inside the body, which can be difficult to see clearly, they looked for circulating tumor cells. These are rare cells that break away from the main tumor and float in the blood, acting as messengers that reveal what the cancer is doing. The team studied thirty-nine patients who were receiving the radioactive PSMA treatment. They used a sophisticated system that combines artificial intelligence with a special type of holographic imaging to catch these cells and examine them without removing them from the blood flow. By staining the cells with glowing markers, the scientists could see which ones still carried the PSMA protein and which ones carried another marker called EpCAM, a common sign of prostate cancer cells. They took samples before the treatment started and again while the patients were undergoing therapy, comparing the results between those who responded well to the drug and those who did not.

The study revealed that the cancer cells did not simply vanish; they changed their appearance. Before treatment, many of the floating cancer cells showed high levels of the PSMA protein, which is why the drug could find them. As the treatment progressed, the proportion of cells that still had PSMA on their surface began to drop. At the same time, the number of cells that had lost PSMA but kept the EpCAM marker increased. This shift happened in both groups of patients, but it was more pronounced in those who responded well to the therapy. The researchers found that patients who saw a larger rise in these PSMA-negative, EpCAM-positive cells were the ones who experienced the best outcomes. This suggests that the treatment might be successfully clearing out the cells it was designed to target, leaving behind a different population of cells that the body or other therapies might handle differently.

However, the presence of certain cells during treatment remained a warning sign. The team discovered that if a patient still had more than five of these circulating cancer cells in their blood while receiving the therapy, their chances of long-term survival were lower. This was particularly true for cells that still carried both the PSMA and EpCAM markers, or for those that carried only PSMA. Even though the treatment was working to reduce the overall number of cells, the fact that some stubborn cells remained in the bloodstream was linked to a shorter life expectancy. Interestingly, the study did not find that a drop in the number of these specific cell types during treatment guaranteed a longer life, suggesting that simply counting how many cells disappear is not the whole story. The real key appears to be the specific mix of cells that remain and how their characteristics shift over time.

Ultimately, this work suggests that watching how these circulating cells evolve offers a new way to judge the success of the radioactive treatment. The findings indicate that the dynamic changes in the types of cells floating in the blood—specifically the rise of cells that have lost the PSMA marker—can predict how long a patient might survive. While the results are not yet a final rule for all cases, they provide a strong reason to keep watching these cell patterns closely. By understanding these shifts, doctors may one day be able to tailor treatments more precisely, knowing early on if the current approach is working or if the cancer is quietly changing its defenses.